Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Not listed in the Ontario formulary extract (2026-08-26).
Patient pays: program not supplied; amount cannot be determined.
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80351
Health Canada: Marketed since 2018-02-01 · brand TRAVATAN Z · ATC S01EE04 TRAVOPROST · form Solution · route Ophthalmic · ingredients TRAVOPROST 0.004 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check on the official e-Formulary (paste DIN 02318008)
DIN 02318008
Shortage status: To be discontinued; reports as of 2026-09-13 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02318008
Source record
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26
DIN 02318008
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02318008
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80351
Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80351, fetched 2026-09-02
Other review policies
For TRAVATAN Z: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
Ontario source; updated September 15, 2026
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.
Ontario source; updated September 15, 2026